Navigation Links
Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
Date:5/26/2008

ase inflammation prior to or during later infusions. ELAPRASE was given more slowly or was stopped early if patients had serious reactions. With these measures, no patients stopped treatment permanently due to an infusion reaction. Because of the potential for life-threatening complications, the ELAPRASE infusion may have to be delayed for patients who have respiratory illness and/or fever.

The most common side effects that required intervention had to do with infusions. These included muscle and joint aches, headache, fever, rash, hives, itching and increased blood pressure. These side effects decreased over time with continued ELAPRASE treatment.

About half of the patients in clinical studies produced antibodies to treatment with ELAPRASE and these patients had an increase in infusion reactions. The presence of antibodies on the effectiveness of ELAPRASE is unknown.

More information about ELAPRASE and Hunter syndrome is available at http://www.elaprase.com or http://www.hunterpatients.com.

About Hunter Syndrome

Hunter syndrome (MPS II) is a serious genetic disorder mainly affecting males that interferes with the body's ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans or GAG. Hunter syndrome is one of several related lysosomal storage diseases.

In Hunter syndrome, cumulative build up of GAG in cells throughout the body interferes with the way certain tissues and organs function, leading to severe clinical complications and early mortality. Physical manifestations for some people with Hunter syndrome may include distinct facial features, a large head and an enlarged abdomen. People with Hunter syndrome may also experience hearing loss, thickening of the heart valves leading to a decline in cardiac function, obstructive airway disease, sleep apnea, and enl
'/>"/>

SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
2. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
3. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
4. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
5. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
6. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
7. BARC Announces Long-Term Cooperation In South African Biobanking for HIV Vaccine Trials
8. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
9. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
10. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
11. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 2015  Giving people with low vision hope – ... International Academy of Low Vision Specialists (IALVS), ... at the forefront of low vision care. The academy ... and latest treatment options available to patients who present ... traditional means. Recently, doctors in six new states and ...
(Date:6/3/2015)... Va. , June 3, 2015  PARI Respiratory Equipment ... Pak ® .  Kitabis Pak, approved by the FDA on ... solution with a PARI LC PLUS ® Nebulizer for ... all the hard work we put into this unique product ... that is easy for patients to use, we also wanted ...
(Date:6/3/2015)...  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ... today announced that it has entered into definitive ... approximately $13.6 million of securities in a registered ... such investors an aggregate of 2,469,091 shares of ... per share. The gross proceeds ...
Breaking Medicine Technology:International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada 2International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada 3International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada 4Kitabis Pak Wins American Package Design Award 2OncoSec Medical Announces $13.6 Million Registered Direct Offering 2OncoSec Medical Announces $13.6 Million Registered Direct Offering 3
(Date:6/3/2015)... The National Resident Matching Program ... Savoia, M.D., Dean of Medical Education at the University of ... on July 1. , “It is an honor ... Matching Program,” said Dr. Savoia. “NRMP’s goal is to ... students with training programs, and I welcome the opportunity to ...
(Date:6/3/2015)... California (PRWEB) June 03, 2015 ... biopharmaceuticals or biologics has revolutionized disease treatment on account ... cancer and autoimmune diseases, such as rheumatoid arthritis. The ... the use of traditional small molecule drugs to biopharmaceuticals ... monoclonal antibodies (mAbs), cell and gene therapies, and recombinant ...
(Date:6/3/2015)... On June 22, 2015, Medicare will begin ... (pharmacogenetic) testing that it has reimbursed since 2009. , ... million of the 49 million Medicare beneficiaries in the U.S. ... drug events.(1) Sadly, if it became a standard of care, ... use of an individual’s genetic information to tailor treatment, is ...
(Date:6/3/2015)... On the heels of a report predicting ... 2020 ( click here to review news coverage about ... Baltimore has the talent to become a world-leading center ... and other biological data are collected and analyzed to help ... all the elements of a perfect storm for bioinformatics leadership,” ...
(Date:6/3/2015)... 2015 Vancouver personal injury lawyers at ... will now handle personal injury claims resulting due to ... rise, more and more people turn towards mass transportation ... needless suffering, serious injury and also deaths. , ... bus accident in BC you may have an ICBC ...
Breaking Medicine News(10 mins):Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 3Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 4Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:Jiwa Law Corporation Now Handles Personal Injury Claims Involving Bus Accidents 2
... ... own the issue of “medication adherence.” , ... Alexandria, VA (Vocus) April 10, 2010 -- An article in ... fueling the National Association of Chain Drug Stores’ (NACDS) message that pharmacy’s role in ...
... Key Topics in Surgical Research and Methodology represents a ... an academic career. Four key elements are covered: ... Research as well as Recent Developments and Future Prospects ... "The aim of this book is to equip surgeons ...
... the United States has experienced a conflict with a ... care, researchers from the University of Chicago report in ... of General Internal Medicine . Younger and less ... than their older or more religious peers. Most primary ...
... say , FRIDAY, April 9 (HealthDay News) -- Doctors ... detect chronic liver disease in children, new research finds. ... (ALT) activity, is designed to detect liver disease or ... assessment of the test levels considered to be signs ...
... begin exercise program early recover faster, reduce sedative use, research ... patients in the intensive care unit may reduce their use ... exercise, a new study has found. , The amount of ... patients to exercise, which reduced the amount of muscle weakness ...
... ... was named a 2009 “Purveyor of the Year” by Outback Steakhouse Inc. (OSI) for ... custom, strategic learning solutions to help cascade strategies throughout its workforce to increase satisfaction ... ...
Cached Medicine News:Health News:New England Journal of Medicine Article Trumpets “Priority” Status of Helping Patients Take Medications Correctly 2Health News:New England Journal of Medicine Article Trumpets “Priority” Status of Helping Patients Take Medications Correctly 3Health News:Primary care physicians nationwide face clinical ethical conflicts with religious hospitals 2Health News:Liver Disease May Go Undetected in Children 2Health News:Mild Exercise Good for the Critically Ill 2Health News:Root Learning Named “Purveyor of the Year” For Strategic Partnership with Outback Steakhouse 2
... 20-year history, the VOYAGER RX Dilatation Catheter ... outcomes. It combines a new low profile, ... shaft,more flexible markers, and short taper balloon ... tortuous anatomy with even greater confidence, opening ...
... Utilizing technology developed over Guidants 20-year history, ... new foundation for successful treatment outcomes. It ... design with a lower profile shaft,more flexible ... you can cross tight and tortuous anatomy ...
... Utilizing technology developed over Guidants 20-year ... the new foundation for successful treatment outcomes. ... tip design with a lower profile shaft,more ... Now you can cross tight and tortuous ...
The assay is an immunometric ('sandwich') EIA for the quantitative measurement of AFP in human serum or plasma....
Medicine Products: